PT2774612T - Formulações de 4-metilpirazol - Google Patents

Formulações de 4-metilpirazol

Info

Publication number
PT2774612T
PT2774612T PT141501387T PT14150138T PT2774612T PT 2774612 T PT2774612 T PT 2774612T PT 141501387 T PT141501387 T PT 141501387T PT 14150138 T PT14150138 T PT 14150138T PT 2774612 T PT2774612 T PT 2774612T
Authority
PT
Portugal
Prior art keywords
methylpyrazole
formulations
methylpyrazole formulations
Prior art date
Application number
PT141501387T
Other languages
English (en)
Inventor
E Daley Thomas
Jarzebinski Olga
Powell Kathy
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of PT2774612T publication Critical patent/PT2774612T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT141501387T 2009-12-07 2010-12-06 Formulações de 4-metilpirazol PT2774612T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26738909P 2009-12-07 2009-12-07

Publications (1)

Publication Number Publication Date
PT2774612T true PT2774612T (pt) 2017-11-17

Family

ID=44145870

Family Applications (2)

Application Number Title Priority Date Filing Date
PT141501387T PT2774612T (pt) 2009-12-07 2010-12-06 Formulações de 4-metilpirazol
PT108364720T PT2467136E (pt) 2009-12-07 2010-12-06 Formulações de 4-metilpirazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT108364720T PT2467136E (pt) 2009-12-07 2010-12-06 Formulações de 4-metilpirazol

Country Status (13)

Country Link
US (2) US9173850B2 (pt)
EP (3) EP2774612B1 (pt)
JP (1) JP5678088B2 (pt)
KR (1) KR101464053B1 (pt)
CN (1) CN102630162B (pt)
AU (1) AU2010328375B2 (pt)
DK (2) DK2774612T3 (pt)
ES (2) ES2646201T3 (pt)
HK (1) HK1201759A1 (pt)
PT (2) PT2774612T (pt)
SG (2) SG10201710156RA (pt)
TW (1) TWI490209B (pt)
WO (1) WO2011071805A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5800669B2 (ja) 2011-10-18 2015-10-28 大阪化成株式会社 抗菌・抗カビ性付与剤、繊維類加工剤及び抗菌・抗カビ性繊維類の製造方法
EP3323412A1 (en) * 2016-11-17 2018-05-23 Amalicon Holding AG Formulation comprising 4-methylpyrazole
KR102150040B1 (ko) * 2018-10-16 2020-08-31 한국과학기술원 4-메틸피라졸을 포함하는 간암 예방 또는 치료용 조성물
CN109452286B (zh) * 2018-11-12 2020-11-06 青岛大学 甲吡唑在杀灭松材线虫中的应用
CN109381458B (zh) * 2018-12-16 2020-09-01 李志武 甲吡唑及其盐在制备抗癫痫药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197787B1 (en) * 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
FR2807645B1 (fr) * 2000-04-12 2005-06-03 Oreal Utilisation d'inhibiteurs de l'alcool deshydrogenase dans le traitement cosmetique des matieres keratiniques
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
ITBO20020284A1 (it) 2002-05-14 2003-11-14 Ima Spa Macchina opercolatrice
AU2003246206A1 (en) 2002-07-05 2004-01-23 Shionogi Qualicaps Co., Ltd. Capsule-filling and -sealing apparatus
ATE531368T1 (de) * 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
AU2004268661A1 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
US20080021083A1 (en) * 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance

Also Published As

Publication number Publication date
US9173850B2 (en) 2015-11-03
SG181566A1 (en) 2012-07-30
KR101464053B1 (ko) 2014-11-20
AU2010328375B2 (en) 2015-08-27
JP2013512930A (ja) 2013-04-18
KR20120115483A (ko) 2012-10-18
SG10201710156RA (en) 2018-01-30
ES2487634T3 (es) 2014-08-22
EP2467136A1 (en) 2012-06-27
CN102630162B (zh) 2014-07-09
JP5678088B2 (ja) 2015-02-25
EP3300732A1 (en) 2018-04-04
TWI490209B (zh) 2015-07-01
ES2646201T3 (es) 2017-12-12
DK2774612T3 (da) 2017-11-20
EP2467136A4 (en) 2013-01-16
HK1201759A1 (en) 2015-09-11
WO2011071805A1 (en) 2011-06-16
DK2467136T3 (da) 2014-08-11
AU2010328375A1 (en) 2012-04-05
EP2774612A1 (en) 2014-09-10
EP2774612B1 (en) 2017-08-30
CN102630162A (zh) 2012-08-08
US20120244217A1 (en) 2012-09-27
EP2467136B1 (en) 2014-05-07
US20160151332A1 (en) 2016-06-02
TW201127816A (en) 2011-08-16
PT2467136E (pt) 2014-08-26

Similar Documents

Publication Publication Date Title
ZA201106050B (en) Dye-polymers formulations
IL219961A0 (en) Abuse-resistant formulations
GB0815435D0 (en) Formulations
GB2459691B (en) Formulations
GB0823269D0 (en) Formulations
IL269369A (en) The vehicles are improved
GB0919210D0 (en) Formulations
GB0821789D0 (en) Formulations
GB0907003D0 (en) Formulation
EP2307021A4 (en) FORMULATIONS
HK1201759A1 (en) 4-methylpyrazole formulations 4-
EP2413905A4 (en) COMPOSITION
ZA201107435B (en) Pyrazole copmpound
IL217390A0 (en) Formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0911213D0 (en) Formulation
GB0822171D0 (en) Temisartan formulations
GB0917744D0 (en) Formulations
GB0914489D0 (en) Improved formulations
GB0811447D0 (en) Formulations
GB0823493D0 (en) Formulations
GB0816876D0 (en) Formulations
GB0817079D0 (en) Formulations
GB0807906D0 (en) Formulations